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he type 1 ryanodine receptor (RyR1) on the sarco-
plasmic reticulum (SR) is the major calcium (Ca
 
2
 
 
 
)
release channel required for skeletal muscle excitation–
contraction (EC) coupling. RyR1 function is modulated by
proteins that bind to its large cytoplasmic scaffold domain,
including the FK506 binding protein (FKBP12) and PKA.
PKA is activated during sympathetic nervous system (SNS)
stimulation. We show that PKA phosphorylation of RyR1 at
Ser
 
2843
 
 activates the channel by releasing FKBP12. When
FKB12 is bound to RyR1, it inhibits the channel by stabilizing
its closed state. RyR1 in skeletal muscle from animals with
T
 
heart failure (HF), a chronic hyperadrenergic state, were
PKA hyperphosphorylated, depleted of FKBP12, and exhibited
increased activity, suggesting that the channels are “leaky.”
RyR1 PKA hyperphosphorylation correlated with impaired
SR Ca
 
2
 
 
 
 release and early fatigue in HF skeletal muscle.
These ﬁndings identify a novel mechanism that regulates
RyR1 function via PKA phosphorylation in response to SNS
stimulation. PKA hyperphosphorylation of RyR1 may
contribute to impaired skeletal muscle function in HF,
suggesting that a generalized EC coupling myopathy may
play a role in HF.
 
Introduction
 
Ryanodine receptors (RyRs)* are calcium (Ca
 
2
 
 
 
) release
channels on the sarcoplasmic reticulum (SR) of striated
muscles that are required for excitation–contraction (EC)
coupling. In skeletal muscle, the type 1 RyR (RyR1) is a
tetramer comprised of four 565,000-D RyR1 polypeptides
and four 12,000-D FK-506 binding proteins (FKBP12).
FKBP12s are regulatory subunits that stabilize RyR channel
function (Brillantes et al., 1994) and facilitate coupled gating
between neighboring RyR channels (Marx et al., 1998) that
are packed into dense arrays in specialized regions of the SR
that release intracellular stores of Ca
 
2
 
 
 
, which triggers
muscle contraction.
In addition to FKBP12, the RyR1 macromolecular complex
includes the catalytic and regulatory subunits of PKA and
protein phosphatase 1 (PP1) (Marx et al., 2001). In skeletal
muscle, EC coupling is triggered by charge movement in the
voltage-gated Ca
 
2
 
 
 
 channel (VGCC) in the transverse tubule
that leads to activation of RyR1, presumably via a direct
interaction between the VGCC and RyR1 (Schneider and
Chandler, 1973; Rios and Brum, 1987). This mechanism is
distinct from that in the heart where the cardiac RyR2 is
activated by Ca
 
2
 
 
 
 influx through the VGCC, a process
known as Ca
 
2
 
 
 
-induced Ca
 
2
 
 
 
 release (Fabiato, 1983; Nabauer
et al., 1989). However, Ca
 
2
 
 
 
-induced Ca
 
2
 
 
 
 release may also
play a role in regulating RyR1 in skeletal-type EC coupling
(Stern et al., 1997).
One FKBP12 molecule is bound to each RyR1 subunit,
and dissociation of FKBP12 increases the open probability
(P
 
o
 
) of the channel (Brillantes et al., 1994; Gaburjakova et
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al., 2001). In addition, dissociation of FKBP12 from RyR1
channels inhibits coupled gating, resulting in channels that
gate stochastically rather than as an ensemble (Marx et al.,
1998). FKBPs are cis–trans peptidyl–prolyl isomerases that
are widely expressed and subserve a variety of cellular func-
tions (Marks, 1996). FKBP12s are tightly bound to and reg-
ulate the function of the skeletal (RyR1) (Jayaraman et al.,
1992; Brillantes et al., 1994) and cardiac (RyR2) (Kaftan et
al., 1996) muscle Ca
 
2
 
 
 
 release channels.
RyR1 and RyR2 channels in skeletal and cardiac muscles,
respectively, are substrates for phosphorylation by PKA,
which activates the channel via an unknown mechanism
(Seiler et al., 1984; Takasago et al., 1989; Suko et al., 1993;
Hain et al., 1995; Valdivia et al., 1995; Marx et al., 2000,
2001; Uehara et al., 2002). PKA is targeted to both skeletal
RyR1 and cardiac RyR2 (Marx et al., 2000, 2001). To gain
a better understanding of the mechanism by which PKA
phosphorylation regulates the function of RyR1, we used
alanine substitution to identify the unique PKA phosphory-
lation site on RyR1 (Ser
 
2843
 
) and generated mutant channels
that either mimic constitutively PKA-phosphorylated RyR1
or cannot be PKA phosphorylated. Constitutively PKA-
phosphorylated RyR1 was unable to bind FKBP12 and ex-
hibited single channel properties similar to those of RyR1
containing mutations in the FKBP12 binding site that also
does not bind FKBP12. To examine the physiologic role of
PKA phosphorylation, we studied channels isolated from
skeletal muscle from animal models of heart failure (HF),
which is a hyperadrenergic state.
RyR1 from canine and rat models of HF was PKA hyper-
phosphorylated and depleted of FKBP12. These biochemical
changes caused increased activity (P
 
o
 
) and increased gating ki-
netics of the RyR1 from HF skeletal muscle. These findings
suggest that FKBP12 stabilizes the open and closed states of
RyR1 and that PKA phosphorylation regulates RyR1 func-
tion, in part, via dissociation of FKBP12. Consistent with the
depletion of FKBP12 from the RyR1 channels from HF skel-
etal muscle, which inhibits RyR1 coupled gating (Marx et al.,
1998), the rate of SR Ca
 
2
 
 
 
 release and the decay of the Ca
 
2
 
 
 
transient were both slowed in HF skeletal muscle (measured
as spontaneous Ca
 
2
 
 
 
 release events or Ca
 
2
 
 
 
 sparks). These de-
fects in RyR1 and SR Ca
 
2
 
 
 
 release were associated with early
fatigue in HF skeletal muscle. Many patients with moderate
degrees of cardiac dysfunction have substantially reduced ex-
ercise capacity that cannot be explained solely by the extent of
their HF (Minotti et al., 1991; Sullivan and Hawthorne,
1995). This has led to the hypothesis that a primary skeletal
muscle defect exists in patients with HF in addition to a pri-
mary cardiac muscle defect.
 
Results
 
PKA phosphorylation of Ser
 
2843
 
 in RyR1 regulates 
FKBP12 binding and activates the channel
 
We identified the PKA phosphorylation site on RyR1 us-
ing site-directed mutagenesis and examined the effects of
PKA phosphorylation of this site on the composition and
function of the RyR1 macromolecular signaling complex
(Marx et al., 2001). Alanine (RyR1-S2843A) and aspartic
acid (RyR1-S2843D) substitutions were used to identify
Ser
 
2843
 
 as the unique PKA phosphorylation site on RyR1
(Fig. 1, A and B). RyR1-S2843A and RyR1-S2843D were
expressed in HEK293 cells with same efficiency as the
wild-type (WT) RyR1 (Fig. 1 A). FKBP12 binding to
RyR1 was assessed by coprecipitation (Fig. 1 C) as previ-
ously described (Gaburjakova et al., 2001). FKBP12 was
detected by immunoblot in the pellet only when bound to
RyR1, otherwise, FKBP12 was detected in the superna-
tant. PKA phosphorylation of RyR1 at Ser
 
2843
 
 (homolo-
gous to the PKA phosphorylation site on RyR2, Ser
 
2809
 
;
Marx et al., 2000) resulted in the dissociation of FKBP12
from WT RyR1, but not from mutant RyR1-S2843A,
which could not be PKA phosphorylated (Fig. 1 C).
FKBP12 bound to the mutant RyR1-S2483A but not to
the mutant RyR1-S2483D, which mimics the constitu-
tively PKA-phosphorylated RyR1. These data establish
Figure 1. FKBP12 binding to RyR1 is regulated by PKA phosphory-
lation of RyR1-Ser
2843. (A) Immunoblot showing that equivalent 
amounts of WT and mutant (RyR1-S2843A and RyR1-S2843D) 
RyR1 were expressed in HEK293 cells. (B) Autoradiograph showing 
PKA phosphorylation of RyR1 using  P
32-ATP (PKI5–24 was used to 
show specificity of the kinasing reaction). Alanine substitution 
identified Ser
2843 as the unique PKA phosphorylation site on RyR1. 
(C) Immunoblot showing binding of FKBP12 to WT and mutant 
RyR1, assessed by centrifugation (FKBP12 cosediments with RyR1) 
and FKBP12 immunoblotting. FKBP12 does not bind to RyR1-S2843D, 
which mimics constitutively PKA-phosphorylated RyR1. (D) Auto-
radiograph showing that activation of PKA bound to RyR1 with 
cAMP causes phosphorylation of the channel, which is inhibited 
by the PKA inhibitor PKI5–24. Activation of PP1 bound to the channel 
with protamine causes dephosphorylation of the channel, which 
is blocked by okadaic acid (OA). (E) FKBP12 immunoblot showing 
that cAMP-induced PKA phosphorylation of RyR1 dissociates 
FKBP12 from the channel complex. FKBP12 cannot bind to the 
PKA-phosphorylated channel, but dephosphorylation of the channel 
with alkaline phosphatase (or by activating bound phosphatases 
with protamine) allows subsequent rebinding of FKBP12 to the 
channel, as assessed by cocentrifugation.T
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that PKA phosphorylation of RyR1 at Ser
 
2843
 
 regulates
binding of FKBP12 to the RyR1 channel.
We previously showed that PKA and PP1 are targeted to
RyR1 via targeting proteins that bind to highly conserved
leucine/isoleucine zipper motifs on the channel (Marx et al.,
2001). PKA bound to RyR1 was activated with cAMP (10
 
 
 
M), causing PKA phosphorylation of RyR1 (Fig. 1 D).
PP1 bound to RyR1 was activated with protamine (1 mg/
ml), causing dephosphorylation of RyR1 (Fig. 1 D). Thus,
PKA and PP1 in the RyR1 macromolecular complex can
regulate phosphorylation/dephosphorylation of the channel
without addition of exogenous kinase or phosphatase.
The effects of activation of PKA in the RyR1 macromo-
lecular complex on FKBP12 binding to RyR1 were assessed
by coprecipitation (Fig. 1 E) as previously described (Gabur-
jakova et al., 2001). cAMP-induced PKA phosphorylation
of RyR1 caused FKBP12 dissociation from RyR1 (Fig. 1 E).
Excess FKBP12 could not bind to the PKA-phosphorylated
RyR1. Inhibiting cAMP-induced activation of bound PKA
with PKI
 
5–24
 
 (500 nM) blocked phosphorylation-induced
dissociation of FKBP12 from RyR1 (Fig. 1 E). After PKA-
phosphorylated RyR1 was dephosphorylated with alkaline
phosphatase (1 U/mg of SR protein) or by activating bound
phosphatase (PP1) with protamine (1 mg/ml), FKBP12
could rebind to the channel (Fig. 1 E). Thus, PKA phos-
phorylation dissociates FKBP12 from RyR1, and FKBP12
cannot rebind to PKA-phosphorylated RyR1.
To determine the functional affects of PKA phosphoryla-
tion of RyR1, we expressed RyR1 in HEK293 cells and re-
constituted recombinant channels in planar lipid bilayers to
examine their single channel properties (Fig. 2 A). WT
RyR1 channels (Fig. 2 A) were compared to (a) mutant
channels that cannot be PKA phosphorylated (RyR1-
S2843A; Fig. 2 B), (b) PKA-phosphorylated WT RyR1 (Fig.
2 C), (c) mutant RyR1 that mimics constitutively PKA-
phosphorylated RyR1 (RyR1-S2843D; Fig. 2 D), and (d)
mutant RyR1 that cannot bind FKBP12 (RyR1-S2461I;
Fig. 2 E). WT RyR1 exhibited the same single channel
properties as native RyR1 (Fig. 2 A; Table I), as previously
reported (Brillantes et al., 1994; Gaburjakova et al., 2001).
Mutant RyR1-S2843A also exhibited the same single chan-
nel properties as native RyR1 (Fig. 2 B).
PKA phosphorylation of RyR1 activated WT RyR1 (in-
creased P
 
o
 
 and decreased open and closed dwell times; Fig. 2
C; Table I). PKA phosphorylation of WT RyR1 was con-
firmed by back phosphorylation (Fig. 1 B). RyR1-S2843A
cannot be activated by PKA, indicating that activation of
WT RyR1 by PKA was due to PKA phosphorylation of
RyR1, because the only difference between the WT and mu-
tant RyR1-S843A channels is that the latter cannot be phos-
phorylated by PKA due to a Ser
 
2843
 
Ala substitution. RyR1-
S2843D exhibited the same single channel properties as
PKA-phosphorylated WT RyR1 (Fig. 2 D; Table I), provid-
ing additional evidence that the affects of PKA phosphoryla-
tion on RyR1 are due to phosphorylation of Ser
 
2843
 
. Thus,
PKA phosphorylation of RyR1 potently activates the chan-
nel at 150 nM cis (cytoplasmic) [Ca
 
2
 
 
 
]
 
cis
 
. Because PKA
phosphorylation of RyR1 causes dissociation of FKBP12
Figure 2. PKA phosphorylation of Ser
2843 activates RyR1 channels. 
(A) Representative single channel tracings of WT RyR1, (B) RyR1-
S2843A, (C) PKA-phosphorylated WT RyR1, (D) RyR1-S2843D, and 
(E) RyR1-V2461I (this mutant RyR1 was previously shown to bind 
FKBP12.6 but not FKBP12; Gaburjakova et al., 2001). RyR1 single 
channel recordings in planar lipid bilayers show activity of the 
channels at 150 nM [Ca
2 ]cis with 1 mM ATP. Recordings were at 0 
mV, closed state of the channels are indicated as C, and openings 
are upwards. All point amplitude histograms are shown. Po and 
mean closed (Tc) and open (To) dwell times are shown above each 
channel tracing.
 
Table I. 
 
PKA phosphorylation activates RyR1
Nonphosphorylated PKA phosphorylated
Open probability Open time Closed time Open probability Open time Closed time
 
ms ms ms ms
 
RyR1 (
 
n
 
 
 
 
 
 21) 0.34 
 
 
 
 0.1
 
a
 
22.1 
 
 
 
 2.4
 
a
 
36.7 
 
 
 
 3.4
 
a
 
0.72 
 
 
 
 0.1
 
a
 
1.6 
 
 
 
 0.6
 
a
 
1.4 
 
 
 
 0.5
 
a
 
RyR1-S2843A (
 
n
 
 
 
 
 
 11) 0.29 
 
 
 
 0.1 25.1 
 
 
 
 2.1 34.4 
 
 
 
 2.4 ND ND ND
RyR1-S2843D (
 
n
 
 
 
 
 
 14) 0.81 
 
 
 
 0.3
 
b
 
1.1 
 
 
 
 0.3
 
b
 
1.9 
 
 
 
 0.8
 
b
 
ND ND ND
 
a
 
P 
 
 
 
 0.001 for nonphosphorylated versus PKA phosphorylated.
 
b
 
P 
 
 
 
 0.001 for RyR1-S2843D versus nonphosphorylated WT.T
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from the channel (Fig. 1 C), we sought to determine
whether the activation of RyR1 by PKA phosphorylation is
due to dissociation of FKBP12 from the channel. To address
this question, we compared the single channel properties of
RyR1-V2461I, which cannot bind FKBP12 due to a muta-
tion in the FKBP12 binding site (Gaburjakova et al., 2001),
with those of PKA-phosphorylated RyR1. RyR1-V2461I ex-
hibited the same changes in single channel properties as
PKA-phosphorylated WT RyR1 and the RyR1-S2843D
mutant channel; increased P
 
o
 
 and decreased open and closed
dwell times compared with nonphosphorylated WT chan-
nels (Fig. 2 E; Table I).
FKBP12.6 is homologous to FKBP12 and is able to bind
to RyR1-V2461I, whereas FKBP12 cannot (Gaburjakova et
al., 2001). We showed previously that the altered single
channel properties of the RyR1-V2461I channels, increased
P
 
o
 
 and decreased open and closed dwell times, can be re-
stored to normal by FKBP12.6 binding to the channel
(Gaburjakova et al., 2001). Thus, the increased P
 
o
 
 and de-
creased open and closed dwell times exhibited by the RyR1-
V2461I mutant channels are specifically due to lack of bind-
ing of FKBP12, rather than some undefined effect of the
mutation on channel structure or function. Taken together,
these data indicate that the activation of RyR1 by PKA
phosphorylation at Ser
 
2843
 
 is specifically due to dissociation
of FKBP12 from the channel.
 
RyR1 PKA hyperphosphorylation and defective 
function in HF skeletal muscle
 
We sought to determine whether RyR1 channels from skele-
tal muscle from animal models of HF (a chronic hyperad-
renergic condition) were PKA hyperphosphorylated and
exhibited altered single channel properties. PKA phosphory-
lation of RyR1 from hind-limb skeletal muscle from a ca-
nine model of pacing-induced HF was assessed using immu-
noprecipitation of RyR1 followed by back phosphorylation
(Fig. 3 A), as described previously (Marx et al., 2000). He-
modynamics showed that left ventricular (LV) dP/d
 
t
 
max
 
 was
3420 
 
 
 
 105 in controls and 1722.2 
 
 
 
 322 in HF (mmHg/s;
 
n
 
 
 
 
 
 4 normal, 
 
n
 
 
 
 
 
 5 HF; P 
 
 
 
 0.01). RyR1 from HF skele-
tal muscle was PKA hyperphosphorylated compared with
RyR1 from normal skeletal muscle (Fig. 3 A): normal 0.4 
 
 
 
0.2, HF 3.6 
 
 
 
 0.8 moles phosphate transferred per mole of
RyR1 channel (
 
n
 
   4 normal, n   5 HF; P   0.01). Thus,
3/4–4/4 PKA sites on each RyR1 channel were phosphory-
lated in HF skeletal muscle, versus  1/4 sites in RyR1 from
normal control skeletal muscle.
We previously showed that PKA hyperphosphorylation of
cardiac RyR2 causes depletion of FKBP12.6 from the chan-
nel macromolecular complex, resulting in channels with al-
tered gating properties in failing hearts (Marx et al., 2000).
Using coimmunoprecipitations (Marx et al., 2000), we
found that there was a significant reduction (approximately
threefold) in the amount of FKBP12 in the RyR1 complex
from HF skeletal muscle compared with controls (n   2
control, n   5 HF; P   0.01; Fig. 3 B); comparable to the
degree of depletion of FKBP12 from the RyR1 complex ob-
served when RyR1 channels from normal skeletal muscle
were subjected to in vitro PKA phosphorylation (Fig. 3 B).
The total amount of cellular FKBP12 (see Fig. 6 C), as well
as the levels of the catalytic subunit of PKA, and the phos-
phatase PP1 in the RyR1 macromolecular complex were not
changed (Fig. 3 C). Thus, PKA hyperphosphorylation of
RyR1 is associated with depletion of FKBP12 from the
RyR1 complex in HF skeletal muscle, analogous to the
PKA hyperphosphorylation–induced depletion of FKBP12.6
from RyR2 in failing hearts (Marx et al., 2000).
HF RyR1 channels had increased Po at cis (cytosolic)
[Ca
2 ] of 100 nM (Fig. 4, A and B; Table II). Normal RyR1
channels are not active at 100 nM [Ca
2 ]cis (Meissner,
1994). HF RyR1 channels exhibited subconductance states
or partial openings (Brillantes et al., 1994) that are rarely ob-
served in RyR1 channels from normal skeletal muscle (Fig. 4
B; Table II). Coupled gating between RyR1 channels, a
mechanism by which clusters of channels open and close si-
multaneously (Marx et al., 1998), was markedly reduced in
HF skeletal muscle channels compared with RyR1 channels
from controls (Table II). The mean open and closed dwell
times were significantly reduced in HF RyR1 compared
with control (Fig. 4, A and B; Table II). Increased Po at
submicromolar [Ca
2 ]cis, decreased open and closed dwell
times, subconductance openings, and reduced coupled gat-
ing are features of recombinant RyR1 expressed without
Figure 3. RyR1 PKA hyperphosphorylation in HF skeletal muscle. 
(A) PKA phosphorylation of RyR1 was measured in skeletal muscle 
homogenates from control normal dogs and dogs with pacing-
induced HF. Equivalent amounts of RyR1 protein were used in each 
kinasing reaction, as shown by immunoblotting. The relative PKA 
phosphorylation of RyR1 from skeletal muscle homogenates from 
normals (n   2) and HF animals (n   5) was determined by dividing 
the specific phosphorylation signal by the amount of RyR1 protein 
(determined by immunoblotting and densitometry). Results are 
expressed as the inverse of the PKA-dependent [ -
32P]ATP signal   
the SD of the mean. (B) The amount of FKBP12 bound to RyR1 was 
assessed by coimmunoprecipitation followed by immunoblotting. 
(C) Representative immunoblots are shown for components of the 
RyR1 macromolecular complex: RyR1, PKA, PP1, and FKBP12 
using samples from normal (n   2) and HF animals (n   5). Protein 
levels were quantified using densitometry of immunoblots. Results 
are expressed as the relative amount of each of the components of 
the RyR1 macromolecular complex corrected for the amount of RyR1 
in each immunoprecipitation. Error bars are SD of the mean.T
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FKBP12 (Brillantes et al., 1994; Marx et al., 1998) and of
native RyR1 after removal of FKBP12 (Ahern et al., 1997;
Marx et al., 1998). Similar defects in RyR1 single channel
properties were observed in RyR1 isolated from skeletal
muscle from FKBP12-null mice, although these animals die
in utero or shortly after birth due to a developmental defect
and skeletal muscle function could not be assessed (Shou et
al., 1998).
Altered SR Ca
2  release in HF skeletal muscle
Ca
2  sparks, which represent SR Ca
2  release from clusters
of individual RyR1, were examined in myotubes from sham-
operated control and HF rat skeletal muscles (Fig. 5 A). SR
Ca
2  release (sparks) amplitude was significantly reduced in
skeletal myotubes from HF muscles with PKA-hyperphos-
phorylated RyR1,  F/F   0.92   0.02 (sham-operated con-
trol) versus 0.76   0.03 in HF (n   6; P   0.01; Fig. 5 B).
HF skeletal muscle Ca
2  sparks exhibited slower rise time
Figure 4. Defective single channel properties of RyR1 isolated 
from skeletal muscle during HF. (A) Single channel traces from an 
RyR1 channel from normal canine skeletal muscle and corresponding 
current amplitude histogram. (B) Single channel traces from an 
RyR1 channel from HF canine skeletal muscle and corresponding 
current amplitude histogram. In A and B, upper tracings were 
recorded at 100 nM [Ca
2 ]cis, and bottom tracings were recorded 
after activation of the RyR1 channels with 1 mM ATP to increase 
Po. Open (To) and closed (Tc) dwell times and Po are shown for each 
condition above the representative tracings. In A and B, the bottom 
tracing is an expanded time scale. Lines indicating the current levels 
(0, 1, 2, 3, 4 pA) for the subconductance states of the PKA-hyper-
phosphorylated channel are shown in the bottom tracing in B. All 
point amplitude histograms for each channel are shown. Recordings 
were at 0 mV, the closed state of the channels is indicated as C, and 
the channel openings are upward deflections.
Table II. Properties of RyR1 channels from normal and HF skeletal muscle
Channels active at 
resting [Ca
2 ]
Channels with substates Channels exhibiting 
coupled gating
a
Open time Closed time
ms ms
Normal skeletal muscle 0/53 (0%) 1/53 (2%) 6/53 (11%) 6.8   1.3 9.7   1.2
HF skeletal muscle 16/42 (38%)
b 33/42 (78%)
c 0/42 (0%)
c 1.4   0.3
c 1.2   0.2
c
aWe previously showed that in normal skeletal muscle,  10% of RyR1 channels remain physically coupled to one another during isolation and insertion
into the bilayer, so the level of coupled gating observed in the present study for RyR1 from control skeletal muscle is comparable to that in normal non-HF
RyR1 (Marx et al., 1998).
bP   0.01 for HF versus normal skeletal muscle.
cP   0.001 for HF versus normal skeletal muscle.
Figure 5. Defects in local Ca
2  signaling in HF skeletal muscle. 
(A)  F/F line scan images of representative examples of Ca
2  sparks 
in muscles from sham and postmyocardial infarction (PMI) HF rats 
and Ca
2  sparks time course. (B) Relative distributions of the spatio-
temporal properties of Ca
2  sparks. Charts indicate 25, 50, 75 
percentiles, the horizontal lines indicate the range from 1–99% of 
the distribution. Sham, open symbols (n   137, three animals); 
postmyocardial infarction (PMI), gray symbols (n   82, two animals). 
*, P   0.05. FDHM, full duration at 1/2 peak amplitude; FWHM, 
full width at 1/2 peak amplitude.T
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(3.98   0.14 [control] vs. 4.66   0.21 ms [HF]; P   0.05)
and prolonged half duration (12.91   0.50 [control] vs.
15.46   0.69 ms [HF]; P   0.05) (Fig. 5 B). Spatial spread
of Ca
2  sparks was larger in the HF skeletal muscles (1.65  
0.03 vs. 1.95   0.09  m; P   0.05; Fig. 5 B). Thus, PKA-
hyperphosphorylated RyR1 is associated with slowed, re-
duced amplitude, longer-lasting SR Ca
2  release events.
RyR1 PKA phosphorylation correlates with defective 
muscle function in HF skeletal muscle
We next sought to determine whether PKA hyperphosphor-
ylation of RyR1 and depletion of FKBP12 from the RyR1
complex are associated with impaired skeletal muscle func-
tion in a rodent postmyocardial infarction HF model. In
this model, HF develops over 6 mo after myocardial infarc-
tion after ligation of the left anterior descending coronary
artery. HF was documented with echocardiography, show-
ing that fractional shortening was reduced to 41.4   4.7%
in HF (n   10) versus 51.6   5.3% in sham-operated con-
trol (n   6; P   0.01); fractional area of contraction was
reduced in HF, 39.1   5.1% versus 68.7   2.4% in con-
trol (P   0.01; HF vs. sham-operated control). Hemody-
namics confirmed HF (LV end diastolic pressure   9.16  
5.19 mm Hg for sham-operated control [n    6] vs.
18.28   8.56 mm Hg for HF [n   10], P   0.05; dP/
dt   5483   1704 mm Hg/s for control vs. 2922   784
mm Hg/s for HF, P   0.01).
RyR1 was PKA hyperphosphorylated in rat HF skeletal
muscle (n    10) compared with sham-operated controls
(Fig. 6 A; n   6, P   0.01), and the amount of FKBP12
bound to RyR1 was depleted by 58% in the HF skeletal
muscle (Fig. 6 B; P   0.01), although the total cellular levels
of FKBP12 were not decreased in HF skeletal muscle (Fig. 6
C). Moreover, in contrast to the cardiac muscle RyR2 mac-
romolecular complex in which PP1 and PP2A levels were
decreased in HF, providing a potential explanation for the
PKA hyperphosphorylation of the RyR2 channel (Marx et
al., 2000), the amount of PP1 in the RyR1 complex was
not decreased in HF skeletal muscle (Fig. 6 B). Recent stud-
ies have reported that the phosphodiesterase PDE4D3 and
the targeting protein muscle A-kinase anchoring protein
(mAKAP) form a signaling complex along with PKA
(Dodge et al., 2001). Because we had previously shown that
PKA is part of the RyR1 macromolecular complex (Marx et
al., 2001) and PKA and mAKAP are components of the
RyR2 complex (Marx et al., 2000), we sought to determine
whether mAKAP and PDE4D3 were present in the RyR1
macromolecular complex. Indeed, using immunoprecipita-
tion with anti–RyR-5029 and immunoblotting with anti-
bodies that detect mAKAP and PDE4D3 (Fig. 6 D), we
found that both mAKAP and PDE4D3 coimmunoprecipi-
tate with RyR1 and therefore are likely part of the RyR1
macromolecular complex (Fig. 6 B). Moreover, compared
with controls (n   4), the amount of PDE4D3 in the RyR1
complex was significantly reduced in HF skeletal muscle
(n   4; P   0.05; Fig. 6 B). The decreased PDE4D3 levels
in the RyR1 channel complex could contribute to a local in-
crease in cAMP and increased PKA activity, which may ex-
plain PKA hyperphosphorylation of RyR1 in HF skeletal
muscle (Fig. 3 A; Fig. 6 A).
HF soleus muscles fatigued earlier and reached tetani
more slowly than muscle from sham controls (Fig. 6, E and
F). The fatigue time was 280   59 s for control soleus mus-
cle compared with 216   26 s for HF soleus muscle (n   5
sham-operated control, n   8 HF; P   0.05; Fig. 6 E). The
tetanus half contraction time was 164.6   70.1 ms for con-
trol soleus muscle compared with 297.5   74.1 ms for HF
soleus muscle (n   5 sham control, n   8 HF; P   0.01;
Fig. 6 F). The demonstration of defective contractile func-
tion, including delayed tetani and accelerated fatigue in HF
Figure 6. RyR1 PKA phosphorylation and muscle fatigue. 
(A) Autoradiogram showing PKA back phosphorylation of RyR1 
from skeletal muscle of sham-operated (control) and HF rats, bar 
graph shows relative PKA phosphorylation of RyR1 (expressed as 
inverse of back phosphorylation as previously described [Marx et 
al., 2000]). (B) Immunoblots and bar graphs showing relative 
amounts of RyR1, mAKAP, PDE4D3, PP1, and FKBP12 immuno-
precipitated with anti-RyR1 antibody from control and HF skeletal 
muscle. (C) Immunoblots showing equal amounts of total cellular 
FKBP12 in control and HF canine and rat skeletal muscles. (D) 
Immunoblots showing RyR1, mAKAP, and PDE4D3 detected in 100 
 g human skeletal muscle SR; negative controls are with antibodies 
preabsorbed with the corresponding antigenic peptides. (E) HF skeletal 
muscle fatigues earlier than control. Rat soleus muscle (n   5 control, 
n   8 HF) was mounted in a tissue bath to assess contractile function 
(see Materials and methods for muscle function protocols). Repre-
sentative fatigue time tracing is shown for control and HF skeletal 
muscles. Bar graph shows mean ( SD) time to fatigue. *, P   0.05. 
(F) HF skeletal muscle achieved tetani more slowly than control. 
Tetani was induced by high-frequency stimulation as described in 
the Materials and methods. Bar graph shows tetani 1/2 contraction 
time. **, P   0.01. (G) Correlation between time to fatigue and 
RyR1 PKA phosphorylation (r   0.88) in rat skeletal muscle from 
sham and HF animals. Muscle function and RyR1 PKA phosphorylation 
were assessed using contralateral soleus muscles from each animal.T
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skeletal muscle, agrees with the findings of others (Perreault
et al., 1993; Lunde et al., 2002). Moreover, the degree of
RyR1 PKA hyperphosphorylation correlated significantly
with early skeletal muscle fatigue (r   0.88; Fig. 6 G). Thus,
PKA hyperphosphorylation of RyR1 and depletion of
FKBP12 from the RyR1 macromolecular complex are asso-
ciated with altered skeletal muscle function.
Discussion
RyRs are involved in signaling in many types of cells, but the
physiologic mechanisms that modulate the function of these
intracellular Ca
2  release channels are not well understood.
One of the best understood systems that involves RyRs is
EC coupling in striated muscles, where RyRs are required
for SR Ca
2  release, which activates muscle contraction.
However, even in skeletal and cardiac muscles, the mecha-
nisms by which systemic signals, such as the sympathetic
nervous system (SNS), modulate RyR function remain to be
elucidated.
The “fight or flight” response is a classic stress pathway
that involves activation of the SNS, leading to  -adrenergic
stimulation of muscle. During SNS stimulation, catechola-
mines bind to  -adrenergic receptors, activate adenylyl cy-
clase via G-proteins, and increase the intracellular levels of
the second messenger cAMP, which activates PKA. In the
present study, we have shown that PKA phosphorylation ac-
tivates RyR1 channels by phosphorylating them on Ser
2843.
This PKA phosphorylation site that we identified using site-
directed mutagenesis agrees with previous studies in which
the same site was identified by phosphopeptide mapping
(Suko et al., 1993). Identification of the PKA phosphoryla-
tion site on RyR1 Ser
2843 allowed us to generate the mutant
RyR1 required to probe the mechanism by which PKA
phosphorylation activates RyR1 channels. This approach al-
lowed us to determine that PKA phosphorylation activates
RyR1 by phosphorylating Ser
2843, which causes dissociation
of FKBP12 from the channel. The dissociation of FKBP12
relieves an inhibition of channel opening that is due to the
stabilization of RyR1 channels in the closed state when
FKBP12 is bound.
Data from the present study provide novel insights regard-
ing the mechanism by which FKBP12 modulates RyR1
function in the context of skeletal muscle EC coupling. The
original studies on the role of FKBP12 in the RyR1 channel
complex suggested that this 12-kD protein was involved in
stabilizing RyR1 channels, possibly via binding to the chan-
nel and stabilizing it in a favorable conformation that is re-
quired for normal physiologic function during EC coupling
(Jayaraman et al., 1992; Brillantes et al., 1994). We now
show that PKA phosphorylation of RyR1 activates the chan-
nel by dissociating FKBP12 from the channel complex. This
finding suggests that one physiologic role of FKBP12 is to
stabilize the closed state of the channel, essentially acting as a
natural channel inhibitor. By releasing FKBP12 from the
channel complex, PKA phosphorylation relieves this inhibi-
tion and activates the channel. PKA phosphorylation of
RyR1 provides a physiologic mechanism for increasing
RyR1 activity. Even though our data indicate that FKBP12
stabilizes RyR1 open and closed states, because RyR1 chan-
nels are opened via an interaction with the VGCC in skeletal
muscle (Schneider and Chandler, 1973; Rios and Brum,
1987), the more important role for FKBP12 in the RyR1
macromolecular complex in skeletal muscle likely is to stabi-
lize the closed state of the channel (i.e., FKBP12 may help
keep RyR1 channels closed when muscle is relaxed and pre-
vent SR Ca
2  leak in skeletal muscle).
To determine the physiologic consequence of our finding
that PKA phosphorylation activates RyR1, which is in agree-
ment with previous reports (Hain et al., 1994; Sonnleitner
et al., 1997), we chose to compare the function of normal
skeletal muscle with those from animal models of HF. HF is
a hyperadrenergic state (Chidsey et al., 1962), and our data
showing that RyR1 is PKA hyperphosphorylated in HF skel-
etal muscle provided us with a model in which we would
compare the function of muscles with and without PKA-
phosphorylated RyR1 in order to probe the role of this form
of regulation of RyR1 in skeletal muscle function.
In skeletal muscle, Ca
2  sparks representing elementary
Ca
2  release events arising from a cluster of RyR1 channels
(Gonzalez et al., 2000) have been technically difficult to
record from adult mammalian skeletal muscle (Shirokova et
al., 1998; Kirsch et al., 2001). In HF skeletal muscle, Ca
2 
sparks exhibited reduced amplitude, slowed rise time, and
prolonged duration. Depletion of FKBP12 from RyR1
might cause an SR Ca
2  leak, which could deplete SR Ca
2 
and contribute to reduced amplitude of SR Ca
2  release
events observed in HF skeletal muscle. The muscle fibers
were saponin skinned, and free [Ca
2 ] was clamped at 130
nM. These conditions likely explain why the spark fre-
quency was not significantly increased in HF skeletal mus-
cle, because the overall spark frequency was very low at rest-
ing [Ca
2 ] of 130 nM. Clamping the free Ca
2  at 130 nM
could also explain why there was not a significant decrease in
SR Ca
2  content in HF skeletal muscle, measured using
acute application of 4-chloro-m-cresol (caffeine analogue),
because SR Ca
2  ATPase activity combined with the low
spark rate, in part due to clamping free Ca
2  at a low (rest-
ing) level, would favor refilling the SR. We have described
coupled gating between RyR1 channels as a mechanism that
enables groups of channels that are physically contacting one
another in the SR membrane to open and close as a single
Ca
2  release unit (Marx et al., 1998). FKBP12 binding to
RyR1 is required for coupled gating (Marx et al., 1998). Re-
duced coupled gating due to FKBP12 depletion could slow
the rate of SR Ca
2  release and impair RyR1 channel clo-
sure, contributing to the prolonged decay of the SR Ca
2  re-
lease transient.
HF skeletal muscles containing PKA-hyperphosphory-
lated RyR1 exhibited prolonged tetani half-contraction
times. Prolonged tetani half-time (meaning that it takes
longer to achieve tetani with the same repetitive stimuli)
could reflect impaired EC coupling, which may occur due to
FKBP12 depletion (Lamb and Stephenson, 1996), although
the specific role of FKBP12 in normal skeletal muscle EC
coupling remains to be elucidated. The early fatigue in HF
skeletal muscle correlates strongly with increased PKA phos-
phorylation of RyR1, suggesting a functional association be-
tween these two findings. Because there is very little Ca
2 
entry or extrusion in skeletal myocytes, they must recycleT
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most of the Ca
2  required for EC coupling. One cost of
compensating for increased SR Ca
2  leakage due to PKA-
hyperphosphorylated RyR1 channels that are depleted of
FKBP12 in skeletal muscle may be increased energy con-
sumption (ATP is required to pump Ca
2  back into the SR
via the Ca
2 -ATPase), which could contribute to the early
fatigue observed in HF skeletal muscle.
The significance of a primary skeletal muscle defect in HF
is underscored by the fact that fatigue in patients does not cor-
relate well with cardiac function (Harrington and Coats,
1997). The problem with skeletal muscle does not appear to
be simply a matter of impaired skeletal muscle blood flow, as
administration of angiotensin-converting enzyme inhibitors
(Drexler et al., 1989) or cardiac transplantation (Stratton et
al., 1994; Sorensen et al., 1999) both increase cardiac output
and skeletal muscle blood flow but do not improve skeletal
muscle function. Studies have documented alterations in skel-
etal muscle energy metabolism in HF, including increased lac-
tate production and turnover (Katz et al., 1993; Wilson et al.,
1993), more rapid breakdown of phosphocreatine, and re-
duced phosphocreatine resynthesis (Mancini et al., 1992).
Defects in SR Ca
2  release channel function and Ca
2  sig-
naling provide a mechanism that could underlie the im-
paired skeletal muscle function in HF. The underlying pa-
thology driving the EC coupling myopathy in cardiac and
skeletal muscles is probably the chronic hyperadrenergic
state that leads to defective SR Ca
2  release channel function
through PKA hyperphosphorylation of both RyR1 and
RyR2. Support for the adverse role of the chronic hyperad-
renergic state in HF comes from recent studies showing that
 -adrenergic receptor blockers improve cardiac function in
HF, reverse PKA hyperphosphorylation of RyR2, and nor-
malize channel function (Reiken et al., 2001; Doi et al.,
2002). However,   blockers have only modest benefit, or
none at all, in terms of improved exercise tolerance in pa-
tients with HF (Kukin et al., 1999; Gullestad et al., 2001).  
blockers have complex effects on skeletal muscle energy me-
tabolism, for example, propranolol inhibits  -adrenergic–
induced activation of both phosphorylase kinase and gly-
cogen synthase (Dietz et al., 1980). Thus, it is possible that
beneficial effects of   blockade, in terms of improved skele-
tal muscle function, could be balanced by adverse effects on
energy metabolism, resulting in only minimal improvement
in exercise tolerance.
Combined with our previous studies (Marx et al., 2000),
the present data indicate that HF may be characterized as a
generalized EC coupling myopathy that affects both forms
of striated muscles, cardiac and skeletal. The underlying pa-
thology that causes this general EC coupling myopathy is
likely the chronic hyperadrenergic state that occurs during
HF. The implications of these new understandings include
the possibility that novel therapeutic targets for HF exist in
the components of the RyR1 and RyR2 macromolecular
complexes that regulate PKA phosphorylation and dephos-
phorylation of the channels.
Materials and methods
Recombinant RyR1
Recombinant WT and mutant RyR1 were expressed, isolated, and charac-
terized as previously described (Brillantes et al., 1994; Gaburjakova et al.,
2001). 48 h after transfection, cells were washed two times, scraped into
PBS, and pelleted by centrifugation at 2,500 g for 5 min at 4 C. Mi-
crosomes were prepared, aliquoted, and stored at  80 C as previously de-
scribed (Gaburjakova et al., 2001).
Immunoblots, immunoprecipitations, and phosphorylation
Skeletal muscle lysates were prepared from 1.0 g of canine tissue or whole
rat soleus muscles homogenized in 1.0 ml of buffer, 50 mM Tris-HCl (pH
7.4), 200 mM NaCl, 20 mM NaF, 1.0 mM Na3VO4, 1.0 mM DTT, and pro-
tease inhibitors. Samples were centrifuged at 3,000 g for 10 min and su-
pernatants stored at  80 C. For immunoprecipitations, skeletal SR samples
were resuspended in 0.5 ml of IP buffer (50 mM Tris-HCl [pH 7.4], 0.9%
NaCl, 0.5 mM NaF, 0.5 mM Na3VO4, 0.25% Triton X-100, and protease
inhibitors) and incubated with anti-RyR antibody overnight at 4 C. Immu-
noblots were performed using the following primary antibodies: anti–PKA
catalytic subunit (1:1,000), anti-PP1 (1:1,000; Transduction Labs), anti-
FKBP (1:1,000; Jayaraman et al., 1992), anti–RyR-5029 (1:3,000; Jayara-
man et al., 1992), anti-PDE4D3 (1:1,000; affinity-purified polyclonal anti-
body raised in rabbits immunized with a mixture of two PDE4D3 peptides,
residues 1–14 of human PDE4D3 with a carboxy-terminal cysteine added
for conjugation to keyhole limpet hemocyanin, and the corresponding rat
sequence that has a T instead of an N at residue 6, MMHVNN/TFP-
FRRHSW[C]), anti-mAKAP (1:750; affinity purified polyclonal antibody
raised in rabbits immunized with a peptide corresponding to mAKAP se-
quence with an amino-terminal cysteine added for conjugation to keyhole
limpet hemocyanin, [C]ETRFNNRQDSDALKSSDD). Protein A–sepharose
beads were added, incubated at 4 C for 1 h, and washed three times with
IP buffer. For phosphorylations, beads were washed with 1X phosphoryla-
tion buffer (8 mM MgCl, 10 mM EGTA, 50 mM Tris/piperazine-N,N’-bis[2-
ethanesulfonic acid], pH 6.8) and resuspended in 10  l of 1.5X phosphor-
ylation buffer containing vehicle alone, PKA catalytic subunit (5 U; Sigma-
Aldrich), PKA plus PKA inhibitor (PKI5–24; 500 nM; Calbiochem), or cAMP
(10  M). Phosphorylation of immunoprecipitated RyR1 was initiated with
MgATP (33  M), [ 
32P]-ATP, and terminated after incubation for 5 min at
RT with 5  l stop solution (4% SDS and 0.25 M DTT). For dephosphoryla-
tion experiments, the cAMP reaction was terminated by addition of PKI,
followed by addition of protamine (1 mg/ml)   okadaic acid (5  M). Sam-
ples were heated to 95 C and size fractionated on 6% SDS-PAGE, and
RyR2 radioactivity was quantified using a Molecular Dynamics Phos-
phorimager and ImageQuant software (Amersham Biosciences). Nonspe-
cific phosphorylation (not inhibited by PKI) was subtracted, and the
32P/RyR1 ratio was calculated by dividing 
32P phosphorylation by the
amount of high-affinity [
3H]ryanodine binding (one high-affinity ryanodine
binding site per RyR1). All experiments were performed in triplicate, and
the investigator was blinded to the source of samples.
FKBP12 binding
Microsomes (200  g) were resuspended in 0.1 ml imidazole buffer (5 mM
imidazole, pH 7.4, and 0.3 M sucrose), containing protease inhibitors, and
incubated with Mg-ATP (100  M) and either PKA (10 U) or cAMP (10  M)
at 30 C for 30 min. Samples were centrifuged at 95,000 g for 10 min, and
supernatants were collected. Pellets were washed twice in 0.2 ml imida-
zole buffer and centrifuged at 95,000 g for 10 min. The final pellet was re-
suspended in 0.1 ml imidazole buffer. In some experiments, pellets were
phosphorylated with cAMP and then dephosphorylated with alkaline
phosphatase (1:100 enzyme/protein) or by activating endogenous phos-
phatases with protamine (1 mg/ml). Recombinant FKBP12 was added to
these samples for 4 h at 4 C to allow binding to RyR1. Pellet and superna-
tant were size fractionated by SDS-PAGE and immunoblotted for FKBP12.
Single channel recordings
SR vesicles from control or HF skeletal muscle, or vesicles from HEK 293
cells transfected with recombinant WT or mutant RyR1 were incorporated
into planar lipid bilayers, and single channel recordings of RyR1 were per-
formed as previously described (Brillantes et al., 1994; Gaburjakova et al.,
2001). Microsomes containing WT RyR1 were phosphorylated with PKA
as described above. Solutions used for channel analysis were as follows:
trans solution (250 mM Hepes, 53 mM Ca[OH]2, 50 mM KCl, pH 7.35)
and cis solution (250 mM Hepes, 125 mM Tris, 50 mM KCl, 1 mM EGTA,
0.5 mM CaCl2, pH 7.35). Free [Ca
2 ] in the cis compartment was calcu-
lated using the Chelator software (Schoenmakers et al., 1992). Single chan-
nel currents were filtered at 1 kHz and digitized at 4 kHz. pClamp 6 (Axon
Instruments, Inc.) was used for analyzing single channel data. Open proba-
bility, the lifetime of open events, and gating frequency were identified by
50% threshold analysis using  2 min of continuous record. At the conclu-
sion of each experiment, ryanodine (5  M) was applied to the cis chamber
to confirm channels as RyRs. Mean open and closed dwell time analysisT
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was performed using Fetchan software (Axon Instruments, Inc.), and open
time distribution was fitted with a two-exponential least-square regression
analysis as previously described (Marx et al., 2001). Data are mean  
SEM. The unpaired t test was used for statistical comparison of mean val-
ues; P   0.05 was considered significant.
Animal models of HF
Rapid LV pacing induced HF as previously described (Wang et al., 1997).
Nine dogs (28–30 kg) were used: (a) normal without heart instrumentation
(n   4) and (b) HF (n   5). After baseline measurements, rapid LV pacing
was initiated at 210 bpm for 3 wks, followed by 1 wk pacing at 240 bpm
with an external pacemaker (EV4543; Pace Medical, Inc.). 12 Sprague-
Dawley (300–400 g) and 2 Wistar rats underwent left coronary ligation via
left thoracotomy, and 6 Sprague-Dawley and 3 Wistar rats underwent
sham operations (control). After 1 wk, echocardiography was performed
on all rats. 6 mo after coronary ligation, echocardiography was repeated,
and hemodynamic data were collected. Animals were then killed and so-
leus muscles harvested.
Ca
2  sparks
Bundles of 4–7 fibers were manually dissected from extensor digitorus lon-
gum muscle in a relaxing solution (in mM: K-glutamate 140, Hepes 10,
MgCl2 10, EGTA 0.1, pH 7.0), mounted as previously described (Lacam-
pagne et al., 1998), and permeabilized in the relaxing solution containing
0.01% saponin for 30–40 s. The solution was changed to an internal me-
dium (in mM: K-glutamate 140, Na2ATP 5, glucose 10, Hepes 10, MgCl2
4.4, EGTA 1.1, CaCl2 0.3, Fluo-3 0.05 [pentapotassium salt; Tef-labs], pH
7.0) used for image recording. Fluorescence images were acquired with a
Carl Zeiss MicroImaging, Inc. LSM 510 NLO confocal system (63x oil im-
mersion, NA 1.4) operated in line-scan mode (x vs. t, 1.9 ms/line). Fluo-3
was excited with an argon/kryton laser at 488 nm, and emitted fluores-
cence was recorded at  525 nm. Potential spark areas were empirically
identified using an autodetection algorithm (Cheng et al., 1999). The mean
F value for the image was calculated by summing and averaging the tem-
poral F at each spatial location while ignoring potential spark areas. This F
value was then used to create a  F/F image pixel by pixel. Selection and
analysis of Ca
2  sparks were performed essentially as previously described
(Klein et al., 1997). Determinations of spatio-temporal properties of indi-
vidual Ca
2  sparks were made on spatial (x) and temporal (t) profiles of
sparks centered at the peak amplitude. The  F/F amplitude as well as tem-
poral parameters, rise time (10–90% of peak  F/F, RT), and duration (full
duration at half-maximum peak amplitude, FDHM) were derived from the
temporal profile. The width of the Ca
2  spark (full width at half-maximum
peak amplitude, FWHM) was determined from the spatial profile. Statisti-
cal comparison of population parameters between the two groups was
conducted using a nonparametric Kruskal-Wallis test.
Muscle function
Soleus muscles were attached to a force transducer in a water bath (Har-
vard Apparatus) and perfused with Krebs-Henseleit containing 2 mM Ca
2 
bubbled with 5% CO2/95% O2. The muscle was rested for 60 min and
then stimulated with single pulses at 10-s intervals. The twitch force,
twitch contraction time, and half-relaxation time were measured. Stimula-
tion was at 1 Hz at 1–30 V. The tetani force, half-contraction time, and
half-relaxation time were also determined by using a stimulating frequency
and titanic duration of 50 Hz and 600 ms (Lunde et al., 2001). Fatigue was
produced by inducing a tetanus every 2 s and measuring the time for force
to fall to 40% of the maximum.
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